Eli Lilly and Company (NYSE:LLY) Shares Sold by Vance Wealth Inc.

Vance Wealth Inc. lowered its position in Eli Lilly and Company (NYSE:LLY) by 9.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 366 shares of the company’s stock after selling 38 shares during the period. Vance Wealth Inc.’s holdings in Eli Lilly and Company were worth $213,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Stonebrook Private Inc. acquired a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $1,493,000. Pitti Group Wealth Management LLC grew its holdings in shares of Eli Lilly and Company by 292.2% in the 4th quarter. Pitti Group Wealth Management LLC now owns 1,659 shares of the company’s stock worth $967,000 after acquiring an additional 1,236 shares during the period. Principle Wealth Partners LLC grew its holdings in Eli Lilly and Company by 10.7% during the 4th quarter. Principle Wealth Partners LLC now owns 6,422 shares of the company’s stock valued at $3,744,000 after buying an additional 620 shares during the last quarter. Transcend Capital Advisors LLC grew its holdings in Eli Lilly and Company by 2.3% during the 4th quarter. Transcend Capital Advisors LLC now owns 14,781 shares of the company’s stock valued at $8,616,000 after buying an additional 336 shares during the last quarter. Finally, Opinicus Capital Inc. acquired a new stake in Eli Lilly and Company during the 4th quarter valued at $2,090,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on LLY. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Citigroup increased their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Truist Financial reiterated a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Finally, BMO Capital Markets increased their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Stock Up 1.2 %

Shares of LLY stock traded up $8.64 during trading hours on Friday, reaching $733.51. The company had a trading volume of 2,009,249 shares, compared to its average volume of 2,265,427. Eli Lilly and Company has a twelve month low of $380.77 and a twelve month high of $800.78. The stock’s fifty day simple moving average is $761.79 and its 200 day simple moving average is $666.67. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The company has a market capitalization of $696.95 billion, a P/E ratio of 126.47, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. During the same quarter last year, the firm earned $2.09 EPS. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. As a group, sell-side analysts expect that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the transaction, the insider now owns 99,488,598 shares in the company, valued at approximately $64,177,109,911.86. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.13% of the stock is owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.